NGL Fine-Chem Ltd.
Snapshot View

3099.75 +108.00 ▲3.6%

23 July 2021, 04:00:00 P.M.
Volume: 5,653

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.nglfinechem.com
Financial Indicators
Market Cap 1,915.03 Cr.
Earnings per share (EPS) 91.81 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 33.76 Trailing Twelve Months Ending 2021-03
Industry PE 35.17 Trailing Twelve Months Ending 2021-03
Book Value / Share 250.01 Trailing Twelve Months Ending 2021-03
Price to Book Value 12.40 Calculated using Price: 3,099.75
Dividend Yield 0.06 Period Ending 2020-03
No. of Shares Subscribed 0.62 Cr. 6,178,024 Shares
FaceValue 5
Company Profile

NGL Fine-chem  is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.

Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.

Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.

It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.

NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.

Product range of the company includes:

Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:

  • Animal health
  • Human health
  • Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
  • Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules

Achievements/ recognition

An ISO 9001:2000 accredited company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+3.61%
1 Week
+2.96%
1 Month
+50.32%
3 Month
+87.72%
6 Month
+161.30%
1 Year
+643.88%
2 Year
+552.10%
5 Year
+1166.76%
2 years 2019-03 2020-03
Return on Equity (%) 21.85 8.72
Return on Capital Employed (%) 25.25 11.93
Return on Assets (%) 13.49 5.40

Balance Sheet View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 92 99
Non Curr. Liab. 12 12
Curr. Liab. 45 49
Minority Int.
Equity & Liab. 149 159
Non Curr. Assets 63 73
Curr. Assets 86 87
Misc. Exp. not W/O
Total Assets 149 159

Profit Loss View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 153 152
Other Income 4 3
Total Income 157 155
Total Expenditure -121 -132
PBIDT 36 23
Interest -3 -3
Depreciation -6 -8
Taxation -7 -4
Exceptional Items
PAT 20 8

Cash Flow View Details

Particulars 2 years 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 9 20
Cash Fr. Inv. -10 -21
Cash Fr. Finan.
Net Change -1 0
Cash & Cash Eqvt 1 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 65.45 73.83 73.83 73.81 73.81 73.81 73.81 73.81 73.81
Public 34.55 26.17 26.17 26.19 26.19 26.19 26.19 26.19 26.19
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 22 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 we are enclosing copy of the newspaper advertisement published in The Free Press Journal & Navshakti.

Kindly take the same on your record.
Thu, 22 Jul 2021
Board Meeting Intimation for Notice Of The Second Board Meeting Of 2021-22 Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015
NGL FINE-CHEM LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2021 inter alia to consider and approve This is to inform you that the second Board Meeting for the financial year 2021-22 of the Board of Directors of NGL Fine-Chem Limited will be held on Friday 30th July 2021 at the Registered Office of the Company at 301 E-Square Subhash Road Vile Parle East Mumbai 400057 at 5.00 p.m.
1. To approve the unaudited Standalone Financial Results for the quarter ended on 30th June 2021.
2. To approve the unaudited Consolidated Financial Results for the quarter ended on 30th June 2021.
3. Any other business with the permission of the chair.

We request you to kindly take this information on record.
Tue, 13 Jul 2021
Shareholding for the Period Ended June 30 2021
NGL Fine Chem Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here

Technical Scans View Details

Fri, 23 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 166,513.85 694.00 +1.0%
Divi's Laboratories Ltd. 128,088.59 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. 90,175.51 5,420.50 +0.7%
Cipla Ltd. 76,510.04 948.50 -0.1%
Cadila Healthcare Ltd. 62,965.29 615.05 -0.9%
Aurobindo Pharma Ltd. 56,484.48 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. 56,291.69 3,915.00 -1.8%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 57.34 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 64.55 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.21 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 31.81 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 29.51 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.59 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 374.38 3,915.00 -1.8%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.58 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 13.78 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.15 5,420.50 +0.7%
Cipla Ltd. Consolidated 2021-03 4.17 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 4.85 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.58 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.25 3,915.00 -1.8%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 0.18 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 10.09 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 3,915.00 -1.8%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 12.53 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 3,915.00 -1.8%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 17,131.99 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 3,915.00 -1.8%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 694.00 +1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,825.00 -0.4%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,420.50 +0.7%
Cipla Ltd. Consolidated 2020-03 1,546.98 948.50 -0.1%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 615.05 -0.9%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 964.00 -0.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 3,915.00 -1.8%